about
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumoursGene expression profiling of breast cancerBasal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotypeHierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.Predicting response and survival in chemotherapy-treated triple-negative breast cancer.Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.Defining breast cancer intrinsic subtypes by quantitative receptor expression.P63 expression in lung carcinoma: a tissue microarray study of 408 cases.PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.Predicting drug responsiveness in human cancers using genetically engineered mice.Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patientsαB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis.Use of mutation profiles to refine the classification of endometrial carcinomas.Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.Metastatic behavior of breast cancer subtypes.MDM2 protein expression is a negative prognostic marker in breast carcinoma.Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.Breast cancer subtypes and the risk of local and regional relapse.The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis.Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
P50
Q24813725-B0792019-57AC-4709-A010-E35F878F8859Q28258697-F86443F6-9ECB-4F2F-8A7C-6FB5C6A44145Q28271274-02678F39-67B4-41B7-9A5B-D8C619B26BBBQ30965944-F7ADC95D-3F55-4B76-B6C6-71DAB016F34AQ31036521-87952ED9-60BA-449E-A5D7-236C317C9E3FQ33291587-5C18CF85-D00D-4BFE-8865-51076026C2F7Q34268261-F39488D2-D789-4C42-8CAD-19B5BBFB4C24Q34354538-11660C0B-50F8-414C-A8B2-62DFD8C51BBEQ34805496-F92F3EF7-E12B-43E1-A508-9F57C31C7095Q35586697-0637CF1E-B23E-4F5B-BE7A-40E2063DEC48Q35954659-D8DBA088-EB45-4EE3-A594-C459D1DA1C83Q36184231-F241DC27-594B-4857-B22B-5F07EDDF74BBQ36337751-5CF98FAC-A1A3-41FF-BEB2-5A0B98442079Q36383626-E1B36BF5-F2C0-49D9-89BF-3D0843CD505EQ36494250-1CEFD91E-31B4-4A07-8498-60DCF2CFB604Q36630430-8CF09C92-2AC5-4A32-80F6-DBE5B7523155Q36758456-7F82E7E7-D654-444B-BC64-EB7941A2D2CEQ37095799-C2DE802D-8098-46DF-A5EB-8D70FD8EC1ECQ37109905-BF91A83C-D473-4D59-9AA7-8E1658677A1FQ37166436-B69FD2B4-2B93-4B95-89FA-D9D6A9125770Q37187379-18340AC7-0618-4DC4-83C3-08C4E2E8DBC7Q37198196-262FEBDD-78F1-4A05-905F-4411958D4D6EQ37244377-5219B0E4-D36E-4150-B1E8-79A83BCED4D8Q37265368-273C6315-133F-43E0-857D-60230E6C5FB1Q37612253-A2A40953-8DF8-47D4-AFED-5C7271ECF2A7Q38410339-222DEBF2-4678-4103-B7D4-6FE540BB51B3Q38416421-1893CEC9-D135-4BBC-B327-C45ED91E9E35Q38440364-ECF71A5D-9FC4-4526-8B4F-CA40E4D49490Q38726645-A9E346DA-383C-4517-820F-89BD6CA8BB45Q38735131-DD53730D-2CFE-4064-921D-B732CB55B912Q39106157-6DEBF1A7-DAEA-48C5-AD65-6AF747754175Q39236297-1D7DE712-B2E5-462B-B25E-53E8883977E8Q40710007-782E1BA7-8F6A-436A-A366-71678450DFDEQ41721517-4E7F2ED1-5A5B-4827-AD61-D4B06E0D29B1Q42439299-E4755002-6363-4820-9735-95251D9188F8Q42468027-6B386738-5E81-46C1-AB9F-496E90A8C0F3Q44814990-FC9981C7-316F-422D-9BCB-29006C449F66Q46396046-3EB6AEDA-B23E-4E0E-9A39-CEE7F49E28EEQ46418293-045AC21C-34C2-48BD-B728-3F703E8D6072Q46758952-871E02E2-2BC2-43DA-8E65-A83919484A19
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maggie Chon U Cheang
@ast
Maggie Chon U Cheang
@en
Maggie Chon U Cheang
@es
Maggie Chon U Cheang
@nl
Maggie Chon U Cheang
@sl
type
label
Maggie Chon U Cheang
@ast
Maggie Chon U Cheang
@en
Maggie Chon U Cheang
@es
Maggie Chon U Cheang
@nl
Maggie Chon U Cheang
@sl
prefLabel
Maggie Chon U Cheang
@ast
Maggie Chon U Cheang
@en
Maggie Chon U Cheang
@es
Maggie Chon U Cheang
@nl
Maggie Chon U Cheang
@sl
P106
P21
P31
P496
0000-0001-5718-2501